Skip to main content

Advertisement

Table 3 Selected clinical studies on advanced-stage and relapsed/refractory NK/T-cell lymphomas

From: The diagnosis and management of NK/T-cell lymphomas

Study (reference) Disease No. Treatment ORR CR OS PFS/DFS
Phase II [67] Newly diagnosed stage IV, relapsed/refractory 38 SMILE 79% 45% 1-year: 55% 1-year: 53%
Retrospective [68] Newly diagnosed stage IV 26 SMILE NR 54% 5-year: 47% 4-year: 60%
Phase III [74] Newly diagnosed, advanced stage 21 DDCP 95% 71% 1-year: 90% 1-year: 86%
21 SMILE 67% 29% 1-year: 57% 1-year: 38%
Phase II [75] Newly diagnosed, advanced stage 22 IMP L-asp 90% 65% 1-year: 76% 1-year: 43%
Phase II [76] Relapsed/refractory 19 AspaMetDex 78% 61% 2-year: 40% 2-year: 40%
Retrospective [68] Relapsed/refractory 44 SMILE 77% 66% 5-year: 52% 4-year: 68%
Retrospective [77] Relapsed/refractory 13 MEDA 77% 61% 1-year: 69% 1-year: 62%
Retrospective [84] Relapsed/refractory 7 Pembrolizumab 100% 71% NR NR
  1. No. number of patients, ORR overall response rate, CR complete response, OS overall survival, PFS progression-free survival, DFS disease-free survival, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide, DDCP dexamethasone, gemcitabine, cisplatinum, pegasparaginase, IMP L-asp ifosfamide, methotrexate, etoposide, prednisolone, L-asparaginase, AspaMetDex L-asparaginase, methotrexate, dexamethasone, MEDA methotrexate, etoposide, dexamethasone, L-asparaginase